Table 4.
Cardiac Events After Completion of T for Patients Receiving IMN RT
| Cardiac Event | AC-T (RT only) |
AC-T-H (RT only) |
AC-TH-H (RT only) |
All RT Patients |
All RT Patients | ||||
|---|---|---|---|---|---|---|---|---|---|
| IMN RT | No IMN RT | IMN RT | No IMN RT | IMN RT | No IMN RT | IMN RT | No IMN RT | ||
| Patients, No. | 15 | 468 | 14 | 508 | 15 | 398 | 44 | 1,374 | 1,418 |
| Confirmed CHF, No. | 0 | 1 | 1 | 13 | 0 | 7 | 1 | 21 | 22 |
| Cardiac deaths, No. | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Cardiac events, No. | 1 | 1 | 1 | 13 | 0 | 7 | 2 | 21 | 23 |
NOTE. Three-year cumulative incidence rates were as follows: AC-T: IMN RT, 0%; no IMN RT, 0.2%; AC-T-H: IMN RT, 7.1%; no IMN RT, 2.6%; and AC-TH-H: IMN RT, 0%; no IMN RT, 1.8%.
Abbreviations: T, paclitaxel; IMN, internal mammary nodes; RT, radiotherapy; AC, doxorubicin and cyclophosphamide; H, trastuzumab; CHF, congestive heart failure.